Multivariable Cox regression analyzing the association of bridging therapy use with overall survival (N=225)
| Variable | HR (95% CI) | SE | P value |
| Months from relapse to CAR T-cell infusion | 0.71 (0.53 to 0.95) | 0.10 | 0.019 |
| ECOG performance status | 1.25 (0.97 to 1.61) | 0.16 | 0.082 |
| LDH >500 (U/L, prior to CAR T-cell infusion) | 1.04 (0.58 to 1.87) | 0.31 | 0.901 |
| CRP >30 (mg/L, prior to CAR T-cell infusion) | 1.78 (1.11 to 2.86) | 0.43 | 0.017 |
| Bridging therapy use | 1.97 (1.24 to 3.14) | 0.47 | 0.004 |
| Dexamethasone dose (dg) from days 0–31 | 1.12 (1.01 to 1.24) | 0.06 | 0.028 |
.CAR, chimeric antigen receptor; CRP, C-reactive protein; dg, decigram; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.